Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024
Period Ending	Dec 31, 2024
Cash & Equivalents	34.77
Cash & Short-Term Investments	34.77
Prepaid Expenses	0.04
Total Current Assets	34.8
Long-Term Deferred Charges	0.8
Other Long-Term Assets	0.01
Total Assets	35.62
Accounts Payable	0.11
Accrued Expenses	9.45
Other Current Liabilities	0.06
Total Current Liabilities	9.61
Long-Term Debt	37.48
Total Liabilities	47.1
Common Stock	0
Additional Paid-In Capital	2.39
Retained Earnings	-17.87
Total Common Equity	-15.48
Shareholders' Equity	-11.48
Total Liabilities & Equity	35.62
Total Debt	37.48
Net Cash (Debt)	-2.72
Net Cash Per Share	-0.51
Filing Date Shares Outstanding	7.05
Total Common Shares Outstanding	7.05
Working Capital	25.19
Book Value Per Share	-2.20
Tangible Book Value	-15.48
Tangible Book Value Per Share	-2.20

Updated Jun 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q